000 04098nam a22004575i 4500
999 _c394888
_d394888
001 394888
003 ES-MaUEC
005 20230103130835.0
006 a||||fo|||| 00| 0
007 cr nn 008mamaa
008 220809s2022 sz | s |||| 0|eng d
020 _a9783030977443
024 7 _a10.1007/978-3-030-97744-3
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRC271 .I45
_b2022 EB
245 0 0 _aCardio-Oncology :
_bManagement of Toxicities in the Era of Immunotherapy
_cedited by Antonio Russo, Nicola Maurea, Dimitrios Farmakis, Antonio Giordano
250 _a1st edition 2022
264 1 _aCham
_bSpringer International Publishing
_c2022
300 _a1 recurso en línea (XIV, 122 páginas)
_b21 ilustraciones, 18 ilustraciones a color
336 _atexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _aarchivo de texto
_bPDF
490 0 _aCurrent Clinical Pathology
_x2197-7828
505 0 _a1. Background: Immunology and cancer -- 2. Available immunotherapy drugs in oncology -- 3. Immunotherapy adverse events -- 4. Pathophysiology of cardiac toxicity -- 5. Cardiac risk factors for immunotherapy -- 6. Diagnostic methods of cardiac immunotherapy damaging -- 7. Biomarkers of early cardiotoxicity -- 8. Management of Patients with Cardiac Toxicity: the point of view of the cardiologist -- 9. Management of patients with cardiac toxicity: the point of view of the oncologist -- 10. Future perspectives.
520 _aThe development of immunotherapy in oncology field has revolutionized the prognosis of many types of cancer. The immune checkpoint inhibitors target receptors whose inhibition increases the activity of immune system cells against tumor cells. In recent years, new immunotherapies have been studied and approved in a growing number of tumors including melanoma, non-small cell lung cancer (NSCLC), and renal cell cancer (RCC). This volume provides a complete and updated state-of-art review regarding the management of cardiovascular toxicities from new immunotherapies. The manuscript is divided into different sections starting from the relationship between cancer and immune system to let the reader understand the new molecular concepts under immunotherapy development. Subsequent chapters describe specifically the immunotherapy options in solid tumor treatment and the main features of the immuno-related cardiovascular complications. This volume is written by experts in the oncological and cardiovascular fields and aims to provide to clinicians who approach current cancer patients a useful tool to move through the paths of modern cardio-oncology. An important section would afford the most relevant interventions needed to manage the cardiac events, suggesting how to reduce their impact and effects on oncological outcomes. The text concludes by addressing future perspectives in the cardio-immunology field, discussing many aspects such as the early detection of cardiovascular damage and the potential role of liquid biopsy in new damage-related biomarkers discovery.
988 _aSpringer_Medicine_2022
650 7 _2embne
_9348509
_aCáncer
_xInmunoterapia
700 1 _aRusso, Antonio
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aMaurea, Nicola
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aFarmakis, Dimitrios
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aGiordano, Antonio
_eeditor literario
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
776 0 8 _iPrinted edition:
_z9783030977436
776 0 8 _iPrinted edition:
_z9783030977450
776 0 8 _iPrinted edition:
_z9783030977467
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-97744-3
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _b01/2023
_dz
_eu
_zSI